Why the study?
Does paclitaxel monotherapy downstage inoperable high-grade splenic angiosarcoma to facilitate surgical resection?
Does paclitaxel monotherapy downstage inoperable high-grade splenic angiosarcoma to facilitate surgical resection?
Paclitaxel monotherapy may be a useful neoadjuvant option to downstage locally advanced splenic angiosarcoma and facilitate surgical resection.
Paclitaxel may offer a neoadjuvant option for inoperable splenic angiosarcoma; single-case evidence leaves open broader applicability.
INTRODUCTION: Splenic angiosarcoma is a rare tumor with only a few cases reported in the literature. Surgical resection offers the best chance of cure for this aggressive neoplasm but is often precluded by infiltration of the tumor to surrounding critical structures. We report a case of a locally advanced angiosarcoma rendered operable by treatment with Paclitaxel monotherapy. CASE PRESENTATION: A 69 year old female presented with a high grade splenic angiosarcoma, considered inoperable due to the extent of local spread. She received three cycles of single agent Paclitaxel and underwent a successful resection of the tumor. CONCLUSION: Chemotherapy options for splenic angiosarcoma are not well studied. Paclitaxel as monotherapy is a useful therapeutic option in down staging tumors, facilitating surgical resection and merits further study in clinical trials.
No takes yet. Share an insight, caveat, or question.
Vakkalanka et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: